The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD
Abstract
OBJECTIVE: Bile acids are regulators of lipid and glucose metabolism, and modulate inflammation in the liver and other tissues. Primary bile acids such as cholic acid and chenodeoxycholic acid (CDCA) are produced in the liver, and converted into secondary bile acids such as deoxycholic acid (DCA) and lithocholic acid by gut microbiota. Here we investigated the possible roles of bile acids in non-alcoholic fatty liver disease (NAFLD) pathogenesis and the impact of the gut microbiome on bile acid signalling in NAFLD. DESIGN: Serum bile acid levels and fibroblast growth factor 19 (FGF19), liver gene expression profiles and gut microbiome compositions were determined in patients with NAFLD, high-fat diet-fed rats and their controls. RESULTS: -taurocholate cotransporting polypeptide and paraoxonase 1, no change in mRNA expression for small heterodimer partner and bile salt export pump, and reduced serum FGF19 were evidence of impaired FXR and fibroblast growth factor receptor 4 (FGFR4)-mediated signalling in NAFLD. Taurine and glycine metabolising bacteria were increased in the gut of patients with NAFLD, reflecting increased secondary bile acid production. Similar changes in liver gene expression and the gut microbiome were observed in high-fat diet-fed rats. CONCLUSIONS: The serum bile acid profile, the hepatic gene expression pattern and the gut microbiome composition consistently support an elevated bile acid production in NAFLD. The increased proportion of FXR antagonistic bile acid explains, at least in part, the suppression of hepatic FXR-mediated and FGFR4-mediated signalling. Our study suggests that future NAFLD intervention may target the components of FXR signalling, including the bile acid converting gut microbiome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Jiao et al. (2018) found that MAFLD patients present elevated primary and secondary bile acids, among which the proportion of DCA is increased and CDCA is decreased.”
From Akkermansia muciniphila alleviates high‐fat‐diet ‐related metabolic‐associated fatty liver disease by modulating gut microbiota and bile acids (2023) · cites this paper as Jiao et al. (2018)
In the citing paper
“Additionally, hepatic CYP7A1 expression is enhanced.”
From Akkermansia muciniphila alleviates high‐fat‐diet ‐related metabolic‐associated fatty liver disease by modulating gut microbiota and bile acids (2023) · cites this paper as Jiao et al. (2018)
In the citing paper
“With increasing severity of NASH and fibrosis, BA levels tend to increase and the composition of BAs changes”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [91]
In the citing paper
“First, the gut microbiota may affect gastrointestinal transit through its regulation of BA synthesis. The gut microbiota is equipped with enzymes for the production of secondary BAs, which may suppress the FGF19- and FXR-mediated signaling, leading to the induction of CYP7A1 [ 49 , 50 ], and consequently elevated de novo BA synthesis and improved colonic transit.”
From Role of gut microbiota in functional constipation (2021) · cites this paper as [49]
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences
Langille, M. G. I., Zaneveld, J., Caporaso, J. G., McDonald, D., Knights, D., Reyes, J. A., Clemente, J. C., Burkepile, D. E., Vega Thurber, R. L., Knight, R., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2676 · Cited by 9,116
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Vernon, G. C., Baranova, A. V., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04724.x · Cited by 3,116
Bile salt biotransformations by human intestinal bacteria
Ridlon, J. M., Kang, D.-J., & Hylemon, P. B. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r500013-jlr200 · Cited by 2,829
Sayin, S. I., Wahlström, A., Felin, J., Jäntti, S., Marschall, H.-U., Bamberg, K., Angelin, B., Hyötyläinen, T., Orešič, M., & Bäckhed, F. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.01.003 · Cited by 2,331
Bile Acids: Natural Ligands for an Orphan Nuclear Receptor
Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1365 · Cited by 2,274
TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis
Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., Macchiarulo, A., Yamamoto, H., Mataki, C., Pruzanski, M., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.08.001 · Cited by 1,885
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C. L., McDonald, J. G., Luo, G., Jones, S. A., Goodwin, B., Richardson, J. A., et al. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.09.001 · Cited by 1,865
Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
Zhu, L., Baker, S. S., Gill, C., Liu, W., Alkhouri, R., Baker, R. D., & Gill, S. R. (2013) · Hepatology · doi:10.1002/hep.26093 · Cited by 1,708
Self-citationFadrosh, D. W., Ma, B., Gajer, P., Sengamalay, N., Ott, S., Brotman, R. M., & Ravel, J. (2014) · Microbiome · doi:10.1186/2049-2618-2-6 · Cited by 1,698
Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., & Staels, B. (2009) · Physiological Reviews · doi:10.1152/physrev.00010.2008 · Cited by 1,678
Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c
渡辺, 光., Houten, S. M., Wang, L., Moschetta, A., Mangelsdorf, D. J., Heyman, R. A., Moore, D. D., & Auwerx, J. H. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21025 · Cited by 1,425
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe
Younossi, Z. M., Blissett, D. B., Blissett, R., Henry, L. L., Stepanova, M., Younossi, Y., Racila, A., Hunt, S., & Beckerman, R. (2016) · Hepatology · doi:10.1002/hep.28785 · Cited by 1,308
Dietary fat intake does affect obesity!
Bray, G. A., & Popkin, B. M. (1998) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/68.6.1157 · Cited by 1,123
Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice
Zhang, Y., Lee, F. Y., Barrera, G., Lee, H., Vales, C., Gonzalez, F. J., Willson, T. M., & Edwards, P. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506982103 · Cited by 974
Min, H., Kapoor, A., Fuchs, M. A., Mirshahi, F., Zhou, H., Maher, J. W., Kellum, J. M., Warnick, R., Contos, M. J., & Sanyal, A. J. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.004 · Cited by 668
Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives
Arab, J. P., Karpen, S. J., Dawson, P. A., Arrese, M., & Trauner, M. (2017) · Hepatology · doi:10.1002/hep.28709 · Cited by 634
Pineda‐Torra, I., Claudel, T., Duval, C., Kosykh, V., Fruchart, J., & Staels, B. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0120 · Cited by 504
Welsh, J. A., Karpen, S. J., & Vos, M. B. (2012) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2012.08.043 · Cited by 481
The bile acid TGR5 membrane receptor: from basic research to clinical application
Duboc, H., Taché, Y., & Hofmann, A. F. (2014) · Digestive and Liver Disease · doi:10.1016/j.dld.2013.10.021 · Cited by 473
Human Insulin Resistance Is Associated With Increased Plasma Levels of 12α-Hydroxylated Bile Acids
Haeusler, R. A., Astiarraga, B., Camastra, S., Accili, D., & Ferrannini, E. (2013) · Diabetes · doi:10.2337/db13-0639 · Cited by 444
The Farnesoid X-receptor Is an Essential Regulator of Cholesterol Homeostasis
Lambert, G. C., Amar, M. J., Guo, G. L., Brewer, H. B., Gonzalez, F. J., & Sinal, C. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209525200 · Cited by 401
Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease
Mouzaki, M., Wang, A. Y., Bandsma, R., Comelli, E. M., Arendt, B. M., Zhang, L., Fung, S., Fischer, S. E., McGilvray, I. G., & Allard, J. P. (2016) · PLOS ONE · doi:10.1371/journal.pone.0151829 · Cited by 385
Degirolamo, C., Rainaldi, S., Bovenga, F., Murzilli, S., & Moschetta, A. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.032 · Cited by 356
Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis
Ferslew, B. C., Xie, G., Johnston, C., Su, M., Stewart, P. W., Jia, W. P., Brouwer, K. L. R., & Barritt, A. S. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3776-8 · Cited by 347
Plass, J. R. M., Mol, O., Heegsma, J., Geuken, M., Faber, K. N., Jansen, P. L. M., & Müller, M. M. (2002) · Hepatology · doi:10.1053/jhep.2002.31724 · Cited by 291
Liver-specific Activities of FGF19 Require Klotho beta
Lin, B. C., Wang, M., Blackmore, C. A., & Desnoyers, L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704244200 · Cited by 288
Influence of Age on Secretion of Cholesterol and Synthesis of Bile Acids by the Liver
Einarsson, K., NILSELL, K., Leijd, B., & Angelin, B. (1985) · New England Journal of Medicine · doi:10.1056/nejm198508013130501 · Cited by 271
Bechmann, L. P., Kocabayoglu, P., Sowa, J., Sydor, S., Best, J., Schlattjan, M., Beilfuss, A., Schmitt, J., Hannivoort, R. A., Kılıçarslan, A., et al. (2013) · Hepatology · doi:10.1002/hep.26225 · Cited by 235
Rao, A., Kosters, A., Mells, J. E., Zhang, W., Setchell, K. D. R., Amanso, A. M., Wynn, G. M., Xu, T., Keller, B. T., Yin, H., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf4823 · Cited by 211
Diet and excretion of bile acids.
Reddy, B. S. (1981) · PubMed · Cited by 208
Brufau, G., Stellaard, F., Prado, K. B., Bloks, V. W., Jonkers, E., Boverhof, R., Kuipers, F., & Murphy, E. J. (2010) · Hepatology · doi:10.1002/hep.23831 · Cited by 198
Yu, J., Lo, J., Huang, L., Zhao, A., Metzger, E., Adams, A., Meinke, P. T., Wright, S. D., & Cui, J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200474200 · Cited by 191
Role of Alcohol Metabolism in Non-Alcoholic Steatohepatitis
Baker, S. S., Baker, R. D., Liu, W., Nowak, N. J., & Zhu, L. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009570 · Cited by 184
Self-citationLiu, W., Baker, S. S., Baker, R. D., Nowak, N. J., & Zhu, L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024363 · Cited by 141
Self-citationReddy, B. S., Mangat, S., Sheinfil, A., Weisburger, J. H., & Wynder, E. L. (1977) · PubMed · Cited by 138
Cariou, B., Chétiveaux, M., Zaïr, Y., Pouteau, E. B., Disse, E., Guyomarch, B., Laville, M., & Krempf, M. (2011) · Nutrition & Metabolism · doi:10.1186/1743-7075-8-48 · Cited by 118
FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption
Jung, D., Inagaki, T., Gerard, R. D., Dawson, P. A., Kliewer, S. A., Mangelsdorf, D. J., & Moschetta, A. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m700351-jlr200 · Cited by 108
Zhu, L., Baker, S. S., Liu, W., Tao, M., Patel, R. A., Nowak, N. J., & Baker, R. D. (2010) · Metabolism · doi:10.1016/j.metabol.2010.10.003 · Cited by 88
Self-citationAlarcon, C., Wicksteed, B. L., & Rhodes, C. J. (2006) · Diabetologia · doi:10.1007/s00125-006-0433-y · Cited by 82
Endotoxemia unrequired in the pathogenesis of pediatric nonalcoholic steatohepatitis
Yuan, J., Baker, S. S., Liu, W., Alkhouri, R. H., Baker, R. D., Xie, J., Ji, G., & Zhu, L. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12510 · Cited by 64
Self-citationSerum Bile Acid Levels in Children With Nonalcoholic Fatty Liver Disease
Jahnel, J., Zöhrer, E., Alisi, A., Ferrari, F., Ceccarelli, S., Vito, R. D., Scharnagl, H., Stojaković, T., Fauler, G., Trauner, M. A., et al. (2015) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000774 · Cited by 60
Gutierrez, A., Ratliff, E. P., Andres, A. M., Huang, X., McKeehan, W. L., & Davis, R. A. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000195793.73118.b4 · Cited by 59
A role for FXR and human FGF-19 in the repression of paraoxonase-1 gene expression by bile acids
Shih, D. M., Kast-Woelbern, H. R., Wong, J., Xia, Y.-R., Edwards, P. A., & Lusis, A. J. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500378-jlr200 · Cited by 48
Paraoxonase 1 and oxidative stress in paediatric non‐alcoholic steatohepatitis
Desai, S. S., Baker, S. S., Liu, W., Moya, D. A., Browne, R. W., Mastrandrea, L. D., Baker, R. D., & Zhu, L. (2013) · Liver International · doi:10.1111/liv.12308 · Cited by 40
Self-citationIncreased apolipoprotein A5 expression in human and rat non-alcoholic fatty livers
Feng, Q., Baker, S. S., Liu, W., Arbizu, R. A., Aljomah, G., Khatib, M., Nugent, C. A., Baker, R. D., Forte, T. M., Hu, Y., et al. (2015) · Pathology · doi:10.1097/pat.0000000000000251 · Cited by 35
Self-citationNovel pathway for iron deficiency in pediatric non-alcoholic steatohepatitis
Moya, D. A., Baker, S. S., Liu, W., Garrick, M. D., Kozielski, R., Baker, R. D., & Zhu, L. (2014) · Clinical Nutrition · doi:10.1016/j.clnu.2014.06.011 · Cited by 20
Self-citation
Research works printed but not linked: 1
- 10.1172/JCI200421025 · DOI
Cited by
Sorted by citations
The gut-liver axis in liver disease: Pathophysiological basis for therapy
Albillos, A., de Gottardi, A., & Rescigno, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.003 · Cited by 2,166
Chait, A., & den Hartigh, L. J. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00022 · Cited by 1,529
“Gut dysbiosis contributes to dysregulated bile acid metabolism (687), leading to hyperlipidemia and hyperglycemia (688, 689).”
BackgroundBile acids and the gut microbiota: metabolic interactions and impacts on disease
Collins, S. L., Stine, J. G., Bisanz, J. E., Okafor, C. D., & Patterson, A. D. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00805-x · Cited by 1,214
Gut-liver axis: Pathophysiological concepts and clinical implications
Tilg, H., Adolph, T. E., & Trauner, M. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.09.017 · Cited by 843
The gut–liver axis and gut microbiota in health and liver disease
Hsu, C. L., & Schnabl, B. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00904-3 · Cited by 737
Metadata
- Authors
- Jiao, N., Baker, S. S., Chapa-Rodriguez, A., Liu, W., Nugent, C. A., Tsompana, M., Mastrandrea, L., Buck, M. J., Baker, R. D., Genco, R. J., Zhu, R., & Zhu, L.
- Affiliations
- Tongji University (CN)
- University at Buffalo, State University of New York (US)
- Department of Pediatrics, Digestive Diseases and Nutrition Center, The State University of New York at Buffalo, Buffalo, New York, USA
- Corresponding author
- Baker, Susan S
- Zhu, Lixin
- ORCID
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2017-08-03
- Volume
- 67
- Issue
- 10
- Pages
- 1881-1891
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2605955022
- Cited by
- 737
- References
- 50
- Citations by year
- 2026: 81 · 2025: 112 · 2024: 128 · 2023: 105 · 2022: 93 · 2021: 83 · 2020: 68 · 2019: 44 · 2018: 17 · 2017: 4
- FWCI
- 15.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Gut (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- GEM Community of Excellence, the University at Buffalo
- the University at Buffalo Departmental Start-Up Fund
- Natural Science Foundation of Shanghai
- National Natural Science Foundation of China
- the Peter and Tommy Fund, Inc., Buffalo, NY
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- non-alcoholic fatty liver disease, bile acids, bile acid signaling, farnesoid X receptor, FGFR4, FGF19, gut microbiota, secondary bile acids, deoxycholic acid, lithocholic acid, taurine metabolism, hepatic gene expression, high-fat diet
- MeSH terms
- Gastrointestinal Microbiome, Receptor, Farnesoid X-Activated, Animals, Bile Acids and Salts, Cholesterol 7-alpha-Hydroxylase, Female, Fibroblast Growth Factors, Humans, Male, Middle Aged, Signal Transduction, Receptors, Cytoplasmic and Nuclear, Gene Expression Profiling, Rats, Diet, High-Fat, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
